Fulvestrant
Hormone Therapy
DB00947
Approved Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
1
Targets
0
Resistance Mutations
3
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Fulvestrant competitively and reversibly binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, fulvestrant binds to the receptors and downregulates them so that estrogen is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms inhibit the growth of tamoxifen-resistant as well as estrogen-sensitive human breast cancer cell lines.
Details
DrugBank ID
DB00947 ↗
Approval Date
2002-04-26
Molecular Weight
606.771 g/mol
Drug Class
Hormone Therapy
ATC Codes
L02BA03
Synonyms
ICI 182,780
PubChem
CID: 17756771 ↗
ChEMBL
CHEMBL1712246 ↗
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])C2[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=CC(O)=CC=C12
ADMET Profile
Computing properties…
Drug References (DrugBank)